Table of Contents

1 Study Coverage

• 1.1 Bio-protein Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Bio-protein Drug Market Size Growth Rate by Product
  • 1.4.2 Monoclonal Antibodies
  • 1.4.3 Therapeutic Proteins
  • 1.4.4 Vaccines
• 1.5 Market by End User
  • 1.5.1 Global Bio-protein Drug Market Size Growth Rate by End User
  • 1.5.2 Pharma and Biotech Companies
  • 1.5.3 CROs
  • 1.5.4 Academics
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Bio-protein Drug Market Size
  • 2.1.1 Global Bio-protein Drug Revenue 2014-2025
  • 2.1.2 Global Bio-protein Drug Sales 2014-2025
• 2.2 Bio-protein Drug Growth Rate by Regions
  • 2.2.1 Global Bio-protein Drug Sales by Regions
  • 2.2.2 Global Bio-protein Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Bio-protein Drug Sales by Manufacturers
  • 3.1.1 Bio-protein Drug Sales by Manufacturers
  • 3.1.2 Bio-protein Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Bio-protein Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Bio-protein Drug Revenue by Manufacturers
  • 3.2.1 Bio-protein Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Bio-protein Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Bio-protein Drug Price by Manufacturers
• 3.4 Bio-protein Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Bio-protein Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Bio-protein Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Bio-protein Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Bio-protein Drug Sales by Product
• 4.2 Global Bio-protein Drug Revenue by Product
• 4.3 Bio-protein Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Bio-protein Drug Breakdown Data by End User

6 North America

• 6.1 North America Bio-protein Drug by Countries
  • 6.1.1 North America Bio-protein Drug Sales by Countries
  • 6.1.2 North America Bio-protein Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Bio-protein Drug by Product
• 6.3 North America Bio-protein Drug by End User

7 Europe

• 7.1 Europe Bio-protein Drug by Countries
  • 7.1.1 Europe Bio-protein Drug Sales by Countries
  • 7.1.2 Europe Bio-protein Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Bio-protein Drug by Product
• 7.3 Europe Bio-protein Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Bio-protein Drug by Countries
  • 8.1.1 Asia Pacific Bio-protein Drug Sales by Countries
  • 8.1.2 Asia Pacific Bio-protein Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Bio-protein Drug by Product
• 8.3 Asia Pacific Bio-protein Drug by End User

9 Central & South America

• 9.1 Central & South America Bio-protein Drug by Countries
  • 9.1.1 Central & South America Bio-protein Drug Sales by Countries
  • 9.1.2 Central & South America Bio-protein Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Bio-protein Drug by Product
• 9.3 Central & South America Bio-protein Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Bio-protein Drug by Countries
  • 10.1.1 Middle East and Africa Bio-protein Drug Sales by Countries
  • 10.1.2 Middle East and Africa Bio-protein Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Bio-protein Drug by Product
• 10.3 Middle East and Africa Bio-protein Drug by End User

11 Company Profiles

• 11.1 Abbott Laboratories
  • 11.1.1 Abbott Laboratories Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Abbott Laboratories Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Abbott Laboratories Bio-protein Drug Products Offered
  • 11.1.5 Abbott Laboratories Recent Development
• 11.2 Bayer AG
  • 11.2.1 Bayer AG Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Bayer AG Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Bayer AG Bio-protein Drug Products Offered
  • 11.2.5 Bayer AG Recent Development
• 11.3 Eli Lilly and Company
  • 11.3.1 Eli Lilly and Company Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Eli Lilly and Company Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Eli Lilly and Company Bio-protein Drug Products Offered
  • 11.3.5 Eli Lilly and Company Recent Development
• 11.4 Amgen Inc.
  • 11.4.1 Amgen Inc. Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Amgen Inc. Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Amgen Inc. Bio-protein Drug Products Offered
  • 11.4.5 Amgen Inc. Recent Development
• 11.5 Biocon Ltd.
  • 11.5.1 Biocon Ltd. Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Biocon Ltd. Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Biocon Ltd. Bio-protein Drug Products Offered
  • 11.5.5 Biocon Ltd. Recent Development
• 11.6 Dr. Reddy’s Laboratories
  • 11.6.1 Dr. Reddy’s Laboratories Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Dr. Reddy’s Laboratories Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Dr. Reddy’s Laboratories Bio-protein Drug Products Offered
  • 11.6.5 Dr. Reddy’s Laboratories Recent Development
• 11.7 Roche
  • 11.7.1 Roche Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Roche Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Roche Bio-protein Drug Products Offered
  • 11.7.5 Roche Recent Development
• 11.8 Fresenius kabi
  • 11.8.1 Fresenius kabi Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Fresenius kabi Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Fresenius kabi Bio-protein Drug Products Offered
  • 11.8.5 Fresenius kabi Recent Development
• 11.9 GlaxoSmithKline
  • 11.9.1 GlaxoSmithKline Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 GlaxoSmithKline Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 GlaxoSmithKline Bio-protein Drug Products Offered
  • 11.9.5 GlaxoSmithKline Recent Development
• 11.10 Johnson & Johnson
  • 11.10.1 Johnson & Johnson Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Johnson & Johnson Bio-protein Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Johnson & Johnson Bio-protein Drug Products Offered
  • 11.10.5 Johnson & Johnson Recent Development
• 11.11 Merck
• 11.12 Novartis AG
• 11.13 Panacea Biotec
• 11.14 ProBioGen AG
• 11.15 Sanofi
• 11.16 Reliance Life Science Pvt. Ltd.

12 Future Forecast

• 12.1 Bio-protein Drug Market Forecast by Regions
  • 12.1.1 Global Bio-protein Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Bio-protein Drug Revenue Forecast by Regions 2019-2025
• 12.2 Bio-protein Drug Market Forecast by Product
  • 12.2.1 Global Bio-protein Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Bio-protein Drug Revenue Forecast by Product 2019-2025
• 12.3 Bio-protein Drug Market Forecast by End User
• 12.4 North America Bio-protein Drug Forecast
• 12.5 Europe Bio-protein Drug Forecast
• 12.6 Asia Pacific Bio-protein Drug Forecast
• 12.7 Central & South America Bio-protein Drug Forecast
• 12.8 Middle East and Africa Bio-protein Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Bio-protein Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Bio-protein Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Bio-protein Drug market based on company, product type, end user and key regions.

This report studies the global market size of Bio-protein Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Bio-protein Drug in these regions.
This research report categorizes the global Bio-protein Drug market by top players/brands, region, type and end user. This report also studies the global Bio-protein Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Abbott Laboratories
Bayer AG
Eli Lilly and Company
Amgen Inc.
Biocon Ltd.
Dr. Reddy’s Laboratories
Roche
Fresenius kabi
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis AG
Panacea Biotec
ProBioGen AG
Sanofi
Reliance Life Science Pvt. Ltd.

Market size by Product
Monoclonal Antibodies
Therapeutic Proteins
Vaccines
Market size by End User
Pharma and Biotech Companies
CROs
Academics

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Bio-protein Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Bio-protein Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Bio-protein Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Bio-protein Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Bio-protein Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Bio-protein Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.